Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).

ABSTRACT:

Purpose

Evaluate patients' and nurses' experiences, including injection problem frequency, with the somatostatin analogues (SSAs) lanreotide autogel^® (Somatuline^® autogel^®, deep subcutaneous) and octreotide long-acting release (LAR) (Sandostatin^® LAR^®, intramuscular) when treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Methods

An observational, cross-sectional study across 2 NET centers in Sweden. Questionnaires based on participants' most recent injection experience were sent to patients with GEP-NETs treated with octreotide or lanreotide, and to nurses administering these treatments. Nurses were identified via patients completing their questionnaires. Resource use was sourced from Swedish prescription

SUBMITTER: Strom T 

PROVIDER: S-EPMC6815752 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature